Fresenius Medical Care

FMS

Market cap $14.5B

Overview Fund Activity

24.71 USD

-0.26

1.04%

At close Updated Sep 15, 4:00 PM EDT

1 day

-1.04%

5 days

-1.79%

1 month

-1.48%

3 months

-13.18%

6 months

2.15%

Year to date

11.56%

1 year

18.06%

5 years

-42.43%

10 years

-38.59%

About: Fresenius Medical Care is the largest dialysis company in the world, treating about 300,000 patients from nearly 3,700 clinics worldwide as of December 2024. In addition to providing dialysis services, the firm is a leading supplier of dialysis products, including machines, dialyzers, and concentrates. Fresenius accounts for about 35% of the global dialysis products market, creating the world's only fully integrated dialysis business. Services account for about three-fourths of sales, while the balance is generated from medical technology products that enable dialysis treatments.

Employees: 112,445

Healthcare Medical Care Facilities

0

Funds holding %

of 7,463 funds

–

Analysts bullish %

Fund manager confidence

Based on 2025 Q2 regulatory disclosures by fund managers ($100M+ AUM)

67% more repeat investments, than reductions

Existing positions increased: 82 | Existing positions reduced: 49

52% more first-time investments, than exits

New positions opened: 32 | Existing positions closed: 21

43% more call options, than puts

Call options by funds: $1.7M | Put options by funds: $1.19M

20% more capital invested

Capital invested by funds: $873M [Q1] → $1.05B (+$174M) [Q2]

4% more funds holding

Funds holding: 198 [Q1] → 205 (+7) [Q2]

5.7% less ownership

Funds ownership: 11.94% [Q1] → 6.24% (-5.7%) [Q2]

See Fund Rankings

Financial journalist opinion

Fresenius Medical Care announces first tranche of its share buyback program of up to EUR 600 million as part of its new capital allocation framework

Total volume of the initial share buyback is up to EUR 1 billion over two years Share buyback to take place until August 10, 2027 BAD HOMBURG, Germany , Aug. 11, 2025 /PRNewswire/ -- Fresenius Medical Care (FME), the world's leading provider of products and services for individuals with renal diseases, announced the launch of the first tranche of its initial EUR 1 billion share buyback, which is part of its new capital allocation framework as presented at its Capital Markets Day on June 17. Today, the first tranche of up to EUR 600 million was initiated, which is planned to be completed at the latest by April 30, 2026.

Fresenius Medical Care announces first tranche of its share buyback program of up to EUR 600 million as part of its new capital allocation framework

Zacks Investment Research

FMS vs. OFIX: Which Stock Should Value Investors Buy Now?

Investors interested in Medical - Instruments stocks are likely familiar with Fresenius (FMS) and Orthofix (OFIX). But which of these two stocks presents investors with the better value opportunity right now?

FMS vs. OFIX: Which Stock Should Value Investors Buy Now?

Zacks Investment Research

FMS Stock Rises as Q2 Earnings Beat Estimates, Revenues Gain Y/Y

Fresenius Medical stock rises as Q2 earnings and revenues top estimates, driven by solid organic growth and expanding margins.

FMS Stock Rises as Q2 Earnings Beat Estimates, Revenues Gain Y/Y

Fresenius Medical Care AG (FMS) Q2 2025 Earnings Call Transcript

Fresenius Medical Care AG (NYSE:FMS ) Q2 2025 Earnings Call August 5, 2025 8:00 AM ET Company Participants s - Corporate Participant o - Corporate Participant P - Corporate Participant Dominik Heger - Executive VP and Head of Investor Relations, Strategic Development & Communications Helen Giza - Chair of Management Board & CEO Martin Fischer - CFO & Member of the Management Board Conference Call Participants David James Adlington - JPMorgan Chase & Co, Research Division Falko Friedrichs - Deutsche Bank AG, Research Division Graham Doyle - UBS Investment Bank, Research Division Hassan Al-Wakeel - Barclays Bank PLC, Research Division Hugo Solvet - BNP Paribas Exane, Research Division James Alexander Stewart Vane- Tempest - Jefferies LLC, Research Division Oliver Metzger - ODDO BHF Corporate & Markets, Research Division Richard Felton - Goldman Sachs Group, Inc., Research Division Veronika Dubajova - Citigroup Inc., Research Division a divi - Unidentified Company ion - Unidentified Company f S& - Global Inc. All Rights reserved. Operator Ladies and gentlemen, welcome to the Report on Second Quarter 2025 Conference Call.

Fresenius Medical Care AG (FMS) Q2 2025 Earnings Call Transcript

Fresenius Medical Care delivers strong organic revenue growth and double-digit operating income growth in the second quarter of 2025

Strong organic revenue growth1 of 7% driven by all operating segments Stable U.S. same market treatment development driven by accelerating patient inflow FME25+ savings of EUR 58 million contributed to earnings Operating income2 grew by 13% at constant currency, further driving margin expansion Stable reported operating income and 20% increase in reported net income3 Operating cash flow improved strongly by 75%, net leverage ratio improved to 2.7x FY 2025 outlook confirmed First tranche of announced share buyback to be initiated in August BAD HOMBURG, Germany , Aug. 5, 2025 /PRNewswire/ -- "In the second quarter of 2025, we further improved our operational performance as strong organic revenue growth and double-digit operating income growth put us fully on track to deliver our full year 2025 financial outlook", said Helen Giza, Chief Executive Officer of Fresenius Medical Care AG. "Organic revenue growth of 7% was supported by all operating segments.

Fresenius Medical Care delivers strong organic revenue growth and double-digit operating income growth in the second quarter of 2025

Zacks Investment Research

Here's Why Fresenius (FMS) Looks Ripe for Bottom Fishing

Fresenius (FMS) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately. This coupled with an upward trend in earnings estimate revisions could mean a trend reversal for the stock in the near term.

Here's Why Fresenius (FMS) Looks Ripe for Bottom Fishing

Zacks Investment Research

Here's Why Fresenius (FMS) is a Strong Value Stock

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

Here's Why Fresenius (FMS) is a Strong Value Stock

Zacks Investment Research

Is the Options Market Predicting a Spike in Fresenius Medical Stock?

Investors need to pay close attention to FMS stock based on the movements in the options market lately.

Is the Options Market Predicting a Spike in Fresenius Medical Stock?

Fresenius Medical Care: Is Trading Below Its Intrinsic Value (Buy)

Fresenius Medical Care (FMS) is rated a buy, with shares up 32.95% YoY and strong Q1 2025 results, showing 60% (YoY) net income growth. My valuation using a forward P/S ratio suggests FMS is undervalued by over 130%, with a projected share price of $62.06 by 2026. Compared to peers, FMS offers the highest potential upside and a superior 3.07% dividend yield, making it an attractive value play.

Fresenius Medical Care: Is Trading Below Its Intrinsic Value (Buy)

Zacks Investment Research

FMS or SONVY: Which Is the Better Value Stock Right Now?

Investors interested in stocks from the Medical - Instruments sector have probably already heard of Fresenius (FMS) and SONOVA HOLDING (SONVY). But which of these two stocks offers value investors a better bang for their buck right now?

FMS or SONVY: Which Is the Better Value Stock Right Now?

See News Rankings

Charts implemented using Lightweight Charts™